A mother wrote a public comment on a cystic fibrosis drug. The White House budget office removed it.

The comment appeared on regulations.gov on a Monday and was gone by the end of the week. No errata note, no retraction language, no reason posted in the docket. The Office of Management and Budget removed it.

OMB is the White House office that writes the administration's budget and oversees the rules that govern how federal money is spent. The comment it pulled came from Magdeleine Bradford-Butcher, a Maryland mother whose toddler takes Trikafta. The drug is the cystic fibrosis treatment that one of Bradford-Butcher's physicians told her gave her daughter a very good chance of outliving her, thanks to the new generation of CF drugs that has changed what a diagnosis means for many patients. Bradford-Butcher's daughter takes it because a routine prenatal screening flagged the genetic mutation, and her doctors put Bradford-Butcher on the drug during pregnancy to head off complications after birth.

Bradford-Butcher's comment was about a specific study her daughter is enrolled in, a clinical trial that follows children given Trikafta in utero. The study is one of the small research efforts that decide whether the drug works as well before birth as it does after, and it is funded through the federal grant pipeline the proposed rule is meant to redirect. The Cystic Fibrosis Foundation and Jessica Knurick, a science communicator who covers rare-disease research, had encouraged her to file the comment.

The rule in question is OMB's proposed "Regulation for Federal Financial Assistance," published in the Federal Register on May 29, 2026. The draft would let political appointees at OMB and across the executive branch decide which federally funded research projects are consistent with administration policy and which grants should be cut for failing that test, according to critics who spoke to Roll Call. The rule is a wholesale rewrite of the body of grant law that has governed how federal research dollars flow to universities, hospitals, and disease foundations. Inside Higher Ed has tracked how the proposal would change political review of grant awards, Michigan researchers told Michigan Public they are already worried about the effects on politically sensitive fields, and CEBN has cataloged the proposed changes for its membership. The comment period closed weeks ago. The proposal is still pending.

Then the comment disappeared. Administrative-law practitioners who track the regulations.gov docket told STAT that the takedown was unusual and that they had not seen the move explained by the agency. The site does not normally erase a comment that has been posted; it may withdraw a duplicate, but it does not erase a substantive public response. A spokesperson for OMB did not respond to STAT's request for an explanation. The office is led by Russell Vought, the administration's budget director.

The deletion matters because regulations.gov is the only place a member of the public can officially weigh in on a federal rule. The site is operated by the government, and the docket is supposed to be a public record. If a comment can be removed without notice, the act of commenting stops being equivalent to speaking into the record and starts being equivalent to speaking into a room where someone can pull the plug.

Bradford-Butcher's comment is now a missing page. There is no archive of what it said, beyond the screenshots she saved and a copy STAT reviewed. OMB has not said whether the takedown was a technical error, a policy choice, or part of a broader review of comments.

Three things to watch. First, the docket for the proposed "Regulation for Federal Financial Assistance," which is still pending at OMB. Second, any on-record statement from OMB about why the comment was removed; silence is the answer for now, and a written explanation would be the first credible reversal. Third, the in-utero Trikafta outcomes study her daughter is enrolled in, which is one of the research grants the proposed rule would expose to politically directed cuts. The trial is small, the patient population is small, and any change in funding would be visible in its enrollment and follow-up cadence.

There is also a procedural lever. The comment is the kind of document that a Freedom of Information Act request can pull from the agency, with a justification for why the page was removed, who removed it, and when. Anyone who has filed a comment on a federal rule in the last year can do the same.